News & Events CTI to Present and Sponsor 2016 Cell & Gene Meeting on the Mesa

CTI to Sponsor and Present at 2016 Cell & Gene Meeting on the Mesa

October 5, 2016

CTI Clinical Trial & Consulting Services to Sponsor and Present at 2016 Cell & Gene Meeting on the Mesa

FOR IMMEDIATE RELEASE - Cincinnati, OH (October 5, 2016)

CTI Clinical Trial and Consulting Services (CTI), a global, privately held, full-service contract research organization, will present at the 2016 Cell & Gene Meeting on the Mesa, taking place in La Jolla, California October 5-7. CTI’s Chief Executive Officer, Timothy J. Schroeder, will present about CTI’s extensive regenerative medicine experience on October 5th at 4:30pm local time.

“We’re honored to be speaking at the 2016 Cell & Gene Meeting on the Mesa, where so many thought leaders in the industry come together,” according to Schroeder. “We believe that CTI's extensive experience in cell and gene therapy, as well as our partnership with the Alliance demonstrate our belief that diagnosis and treatment paradigms will change dramatically in the near future based on these advances."

CTI is also a supporting member of the Alliance for Regenerative Medicine, and is a proud sponsor of the 2016 Cell & Gene Meeting on the Mesa.

Schroeder has over 35 years of clinical, academic, and industry experience in global drug and device development programs. Prior to founding CTI nearly two decades ago, he held numerous faculty positions with the University of Cincinnati College of Medicine. Schroeder was also the founding Executive Vice President of Clinical Development at SangStat Medical Corporation, which went public in 1995. He is currently a board member for over a dozen corporate and non-profit organizations, including Xavier University, which he attended. 

About the Cell and Gene Meeting on the Mesa

Organized by Alliance for Regenerative Medicine (ARM) and the Sanford Consortium for Regenerative Medicine, the Cell & Gene Meeting on the Mesa is three-day conference featuring three distinct parts, the program’s two-day Partnering Forum, a Public Forum lecture and a full-day Scientific Symposium. This year’s event will attract more than 800 attendees, including senior executives from leading cell therapy, gene therapy and tissue engineering companies worldwide, large pharma and biotech, institutional investors, academic research institutions, patient foundations and disease philanthropies, life science media and more. A live video webcast of all company presentations will be available at: http://www.meetingonthemesa.com/webcast/ and will also be published on ARM’s website shortly after the event. Please visit www.meetingonthemesa.com/ for full information including registration. Investors should contact Laura Parsons at lparsons@alliancerm.org and interested media should contact Lyndsey Scull at lscull@alliancerm.org. 

About CTI Clinical Trial and Consulting Services

CTI Clinical Trial and Consulting Services is a global, privately held, full-service contract research organization (CRO), delivering a complete spectrum of clinical trial and consulting services throughout the lifecycle of development, from concept to commercialization. CTI’s focused therapeutic approach provides pharmaceutical, biotechnology, and medical device firms with clinical and disease area expertise in rare diseases, regenerative medicine/gene therapy, immunology, transplantation, nephrology, hematology/oncology, neurology, infectious diseases, hepatology, cardiopulmonary, and pediatric populations. CTI also offers a fully integrated multi-specialty clinical research site that conducts phase I-IV trials. CTI has a passion for helping life-changing therapies succeed in chronically and critically ill patient populations. With clinical trial experience across 6 continents, CTI partners with research sites, patients, and sponsors to fulfill unmet medical needs. CTI is headquartered in Cincinnati, OH, with operations across North America, Europe, Latin America, and Asia-Pacific. For more information visit www.ctifacts.com

Subscribe to our mailing list

* indicates required